Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021121 | 1.00 | APP (0.57) | APPTDP1KDM4ERECQLTSHR | |
| SCHEMBL1235262 | 1.00 | APP (0.57) | APPTDP1KDM4ERECQLTSHR | |
| SCHEMBL16758740 | 1.00 | APP (0.57) | APPTDP1KDM4ERECQLTSHR | |
| SCHEMBL5357 | 0.94 | TDP1 (0.59) | APPTDP1KDM4ERECQLTSHR | |
| SCHEMBL15814832 | 0.92 | APP (0.50) | APPTDP1KDM4ERECQLTSHR | |
| SCHEMBL15071342 | 0.89 | APP (0.67) | APPTDP1KDM4ETSHRNPC1 | |
| SCHEMBL3611926 | 0.89 | KDM4E (0.61) | APPTDP1KDM4ERECQLMAPK1 | |
| SCHEMBL12703538 | 0.89 | KDM4E (0.61) | APPTDP1KDM4ERECQLMAPK1 | |
| SCHEMBL1353069 | 0.89 | APP (0.67) | APPTDP1KDM4ETSHRNPC1 | |
| SCHEMBL7911522 | 0.89 | APP (0.67) | APPTDP1KDM4ETSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388435-B1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2188271-B1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | UNIV LEICESTER (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9221756-B2 | Pyrrole derivatives | UNIVERSITY OF LEICESTER (GB) | 2015-12-29 | — | — | US | disclosed |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | UNIVERSITY OF LEICESTER (GB) | 2014-10-16 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055990-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013044361-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013044361-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2009023402-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
| EP-0745894-B1 | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK CO (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-0745894-A1 | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5500338-A | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | APP 4861/4885TDP1 2861/4885KDM4E 2327/4885 |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | APP 4580/4885TDP1 919/4885KDM4E 3367/4885 |
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | APP 2881/4885TDP1 971/4885KDM4E 1392/4885 |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | APP 2881/4885TDP1 971/4885KDM4E 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.